Briefings

In the Research Briefing of July 8th 1) Sustained improvements in well-being after psychedelic experiences 2) Psychedelic shift metaphysical beliefs away from materialistic 3) Treating anorexia with psychedelics looks promising

In the Research Briefing of June 24th 1) Are patients ready for psychedelics as medicines? A survey study provides answers 2) Microdosing for creativity still not catching a break 3) Ketamine helps those with chronic migraines find temporary relief

In the Research Briefing of June 10th 1) Using machine learning to predict who will quit alcohol and opioids after a psychedelic trip 2) Positive outcomes after an ayahuasca retreat, with improvements at the 6-month follow-up 3) The fMRI data for psychedelic neuroimaging is less organized than one hopes for

In the Research Briefing of June 3rd 1) Reducing negativity bias in depressed patients with psychedelics 2) Psychedelic trials focus mainly on MDMA and psilocybin at this time 3) Positive long-term outcomes after bad trips and a more complete picture of such experiences

In the Research Briefing of May 27th 1) The intensity of an LSD experience as predicted by your genes 2) A brain on psilocybin becomes less segregated 3) Bringing people from different worlds together through ayahuasca

In the Research Briefing of May 19th 1) The most complete picture we have of our brains on LSD 2) Psychedelics may help us explore consciousness, we should also be aware of what we can’t explain

In the Research Briefing of May 12th: 1) MAPS reports a successful trial of MDMA-assisted therapy for PTSD 2) Moving past mysticism in psychedelic research 3) Psychedelic users appear to be more resilient in the face of Covid

In the Research Briefing of May 6th: 1) A new biosensor helps identify which molecules are hallucinogenic 2) Microdosing and awe, experiencing the sublime on psilocybin 3) Large meta-analysis finds esketamine lowers depression scores

In the Research Briefing of April 21st: 1) Psilocybin pitted against antidepressant and wins on many accounts 2) What if the anti-depressant and hallucinogenic effects of psychedelics are independent?

In the Research Briefing of April 14th: 2) Creativity is impaired whilst under the influence of psilocybin 2) Ethical and legal considerations for clinicians with patients who use psychedelics 3) Psychedelics make it to the ‘New England Journal of Medicine’